Sign in
CompletedNo phase

Study on Surgical Treatment Strategies for Moderate Ischemic Mitral Regurgitation

Key facts

Who runs it
China National Center for Cardiovascular Diseases
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
464 people enrolled
Started
1 Aug 2023
Ended
1 Apr 2024
Type of study
Observational, 2 groups
Treatments tested
  • mitral valve repair
Record updated
16 May 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Adult coronary artery disease patients complicated with moderate ischemic mitral regurgitation
  • undergoing coronary artery bypass grafting with or without mitral valve repair

Who cannot take part

  • patients undergoing concomitant aortic valve procedure
  • patients complicated with primary mitral valve disease other than ischemic mitral regurgitation, such as rheumatic mitral regurgitation or mitral valve leaflet prolapse,
  • patients under the age of 18 years,
  • patients complicated with more than moderate ischemic mitral regurgitation or undergoing mitral valve replacement,

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aimed to compare the efficacy of isolated coronary artery bypass grafting and coronary artery bypass grafting + mitral valve repair in moderate ischemic mitral regurgitation patients through a cohort and explore the potential risk factors of the clinical outcomes.

The 2 groups in the trial

  • coronary artery bypass grafting

    Treatment: mitral valve repair

  • coronary artery bypass grafting concomitant mitral valve repair

    Treatment: mitral valve repair

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 May 2024